BioSpace News Archive

Lipella Pharmaceuticals Inc. announced today that it has been granted “Orphan Drug Designation” from the U.S. Food and Drug Administration (FDA) for its drug candidate, LP-310, which has been designed for the treatment of oral Graft-versus-Host Disease (GvHD).

Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS), will be presented at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting from Nov. 16 to Nov. 19 in Vancouver, Canada.

Immunome, Inc. today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET.

Sagimet Biosciences Inc. announced the presentation of preclinical results detailing artificial intelligence based digital pathology of Sagimet’s FASN inhibitor alone or in combination with semaglutide in a preclinical mouse model of nonalcoholic steatohepatitis.

Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced it will present a late-breaking oral presentation and a poster featuring its lead product candidate efruxifermin (EFX) at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023 being held November 10-14 in Boston, MA.

Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from an expansion cohort of STELLAR-001 evaluating single-agent zanzalintinib in patients with previously treated clear cell renal cell carcinoma (ccRCC).

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that it will participate in the Jefferies London Healthcare Conference.

According to Vision Research Reports, the global digital therapeutics market size was surpassed at USD 3.91 billion in 2022 and is expected to hit around USD 25.32 billion by 2032, growing at a CAGR of 20.54% from 2023 to 2032.

Partners STADA and Alvotech announced that the Committee for Medicinal Products for Human Use within the European Medicines Agency has adopted a positive opinion for Uzpruvo, a biosimilar candidate to Stelara®.

PsychoGenics Inc., the leading contract research organization specializing in central nervous system focused preclinical and translational drug discovery services, is proud to unveil its refreshed corporate identity and brand.